Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations

Clinical and Applied Thrombosis/Hemostasis

Volumn 9, Issue 4, 2003, Pages 293-297

  Leong, Wendy ^a   Hoppensteadt, Debra A ^a  

^a Box 425 ^*

Author keywords

Bioequivalence; Generic; LMWH (low molecular weight heparin); Therapeutic interchangeability

Indexed keywords

ALTEPLASE; ANTICOAGULANT AGENT; CERTOPARIN; CUTENOX; DALTEPARIN; ENOXAPARIN; GENERIC DRUG; LOW MOLECULAR WEIGHT HEPARIN; MARKAPARIN; NADROPARIN; PARNAPARIN; RAVIPARIN; TARO WARFARIN; TINZAPARIN; UNCLASSIFIED DRUG; WARFARIN;

BIOEQUIVALENCE; CONSUMER; COST; DRUG APPROVAL; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0242691926     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960300900404     Document Type: Review

References (18)

1. Merli G, Vanscoy G, et al. Applying scientific criteria to therapeutic interchange: A balanced analysis of low molecular weight heparins. J Thromb Thrombolysis 2001; 11(3):247.
2. American Society of Hospital Pharmacists. ASHP statement on the formulary system. Am J Hosp Pharmacol 1988;43;2839.
3. McCart GM, Kayser S. Therapeutic equivalency of low molecular weight heparins. Ann Pharmacother 2002; 36:1042.
4. Prandoni P. Low molecular weight heparins: Are they interchangeable? Yes. J Thromb Hemost 2003;1:10.
5. Nenci G. Low molecular weight heparins: Are they interchangeable? No. J Thromb Hemostas 2003;1:12.
6. Bick RL, Fareed J. Low molecular weight heparin: Differences and similarities in approved preparations in the United States. Clin Appl Throm Hemost 1999;5(Suppl 1):S63.
7. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM. Low molecular weight heparins. Are they different? Can J Cardiol 1998;14(Suppl E):28E.
8. Fareed J, Haas S, Sasahara A. Past, present and future considerations on low molecular weight heparins differentiation: An epilogue. Semin Thromb Hemost 1999; 25(Suppl 3):145.
9. Nightingale SL. From the Food and Drug Administration. JAMA 1993;270(14):1672.
10. Hirsch J, Warkentin TE, et al. Heparin and low molecular weight heparin: Mechanisms of action, pharamcokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114(Suppl 5):489S.
11. Ryan TJ, Antman EM, et al. 1999 update ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1999;34(3):890.
12. Fareed J, Fu K, et al. Pharmacokinetics of low molecular weight heparins in animal models. Semin Thromb Hemost 1999;25(Suppl 3):51.
13. Kaiser B, Kirchmaier CM, et al. Preclinical biochemistry and pharmacology of low molecular weight hepains in vivo. Semin Thromb Hemost 1999;25(Suppl 3):35.
14. Cohen M, Demers C, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events study group (ESSENCE). N Engl J Med 1997;337(7):447.
15. Klein W, Buchwald A, et al. Fragmin in unstable angina pectoris or in non-Q wave acute myocardial infarction. Fragmin in unstable coronary artery disease (FRIC). Am J Cardiol 1997;80(5A):30E.
16. FRISC study group. Low molecular weight heparin during instability in coronary artery disease. Fragmin during instability in coronary artery disease (FRISC). Lancet 1998;347(9001):561.
17. Mousa S, Fareed J. Overview: From heparin to low molecular weight heparins: Beyond anticoagulation. Curr Opin Invest Drug 2001;2(8):1077.
18. Hirsch J, Fuster V, et al. American Heart Association/ American College of Cardiology foundation guide to warfarin therapy. Circulation 2003;107:1692.